The pathogenesis of Staphylococcus aureus in the trauma patient and potential future therapies

American Journal of Surgery

Volumn 172, Issue 3, 1996, Pages 291-296

  Villavicencio, Raphael T ^a   Wall Jr , Matthew J ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFALEXIN; EXOTOXIN; LEUKOCIDIN; METICILLIN; PENICILLIN BINDING PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; HUMAN; INJURY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS;

EID: 0030249324     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00102-X     Document Type: Article

References (76)

1. 1. File TM, Tan JS. Treatment of skin and soft-tissue infections. Am J Surg 1995;169(suppl. 5A):27S-32S.
2. 2. Antimicrobial prophylaxis in surgery. Abramowicz M. The Medical Letter. 1993;35:91-94.
3. 3. Stillwell M, Caplan ES. The septic multiple-trauma patient. Infect Dis Clin North Am. 1989;3:155-183.
4. 4. Babineau TJ, Marcello P. Randomized phase I/II trial of a macrophage-specific immunomodulator(PGG-Glucan) in high-risk surgical patients. Ann Surg. 1994;220:601-609.
5. 5. Noble WC. Factors controlling the microflora of the skin. In: Hill MJ, Marsh PD, eds: Human Microbial Ecology. Boca Raton: CRC Press, 1990:131-153.
6. 6. Bjornson HS. Microbiology of surgical infection. In: Meakins JL, ed. Surgical Infections: Diagnosis and Treatment. New York: Scientific American, 1994:1-12.
7. 7. Shuter J, Hatcher VB, Lowy FD. Staphylococcus aureus binding to human nasal mucin. Infect Immun 1996;64:310-318.
8. 8. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Ann Rev Microbiol. 1994;48:585-617.
9. 9. Patti JM, Hook M. Microbial adhesins recognizing extracellular matrix molecules. Curr Opin Cell Biol. 1994;6:752-758.
10. 10. Cheung AI, Projan SJ, Edelstein RE, Fischetti VA. Cloning, expression, and nucleotide sequence of a Staphylococcus aureus gene (fbpA) encoding a fibrinogen-binding protein. Infect Immun. 1995;63:1914-1920.
11. 11. Foster TJ, McDevitt D. Molecular basis of adherence of Staphylococci to biomaterials. In: Bisno AL, Waldvogel FA, eds. Infections Associated with Indwelling Medical Devices, 2nd ed. Washington, DC: American Society for Microbiology, 1994:31-44.
12. 12. Patti JM, Bremell T, Krajewska-Pietrasik D, et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun. 1994;62:152-161.
13. 13. Moreillon P, Entenza JM, Francioli P, et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun. 1995;63:4738-4743.
14. 14. McGavin MH, Krajewska-Pietrasik D, Ryden C, Hook M. Identification of a Staphylococcus aureus extracellular matrix-binding protein with broad specificity. Infect Immun. 1993;61:2479-2485.
15. 15. McDevitt M, Francois P, Vaudaux P, Foster TJ. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol. 1995;16:895-907.
16. 16. Jonsson K, McDevitt D. Staphylococcus aureus expresses a major histocompatibility complex class II analog. J Biol Chem. 1995;270:21457-21460.
17. 17. Unanue ER. Cellular studies on antigen presentation by class II MHC molecules. Curr Opin Immunol. 1992;4:63-69.
18. 18. Sompolinsky D, Samra Z. Encapsulation and capsular types in isolates of S. aureus from different sources and relationship to phage types. J Clin Microbiol. 1985;22:828-834.
19. 19. Soell M, Diab M, Haan-Archipoff G, et al. Capsular polysaccharide Types 5 and 8 of S. aureus bind specifically to human epithelial (KB) cells, endothelial cells, and monocytes and induce release of cytokines. Infect Immun. 1995;63:1380-1386.
20. 20. Karakawa WW, Sutton A. Capsular antibodies induce type-specific phagocytosis of capsulated S aureus by human polymorphonuclear leukocytes. Infect Immun. 1988;56:1090-1095.
21. 21. Ryding U, Christensson B, Soderquist B, Wadstrom T. Antibody response to Staphylococcus aureus collagen binding protein in patients with Staphylococcus aureus septicaemia and collagen binding properties of corresponding strains. J Med Microbiol. 1995;43:328-334.
22. 22. Tokura Y, Yagi J, O'Malley M, et al. Superantigenic staphylococcal exotoxins induce T-cell proliferation in the presence of Langerhans cells or class II-bearing keratinocytes and stimulates keratinocytes to produce T cell-activating cytokines. J Invest Dermatol. 1994;102:31-38.
23. 23. Chu T, Jaffe R. The normal Langerhans cell and the LCH cell. Br J Cancer, 1994;23(suppl):S4-S10.
24. 24. Davies MG, Haggen P. The vascular endothelium: a new horizon. Ann Surg. 1993;218:563-609.
25. 25. Yao L, Bengualid V, Lowy FD, et al. Internalization of S. aureus by endothelial cells induces cytcikine gene expression. Infect Immun. 1995;63:1835-1839.
26. 26. Konig B, Prevost G, Piemont Y, Konig W. Effects of S. aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis. 1995;171:607-613.
27. 27. Colin DA, Muzurier I, Sire S, Finck-Barbancon V. Interaction of the two compounds of leucocidin from Staphylococcus aureus with human polymorphonuclear leukocyte membranes: sequential binding and subsequent activation. Infect Immun. 1994;62:3184-3188.
28. 28. Prevost G, Cribier B, Couppie P, et al. Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun. 1995;63:4121-4129.
29. 29. Timmerman CP, Mattsson E, Martinez-Martinez L, et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun. 1993;61:4167-4172.
30. 30. Parsonnet J, Gillis ZA. Production of tumor necrosis factor by human monocytes in response to toxic-shock syndrome toxin-1. J Infect Dis. 1988;158:1026-1033.
31. 31. Ferrante A, Martin AJ, Bates EJ, et al. Interaction of S. aureus with human neutrophils and the down-regulation of TNF receptors. J Immunol. 1994; 152:3998-4004.
32. 32. Hensler T, Koller M, Geoffroy C, et al. Staphylococcus aureus toxic shock syndrome toxin 1 and Streptococcus pyogenes erythrogenic toxin A modulate inflammatory mediator release from human neutrophils. Infect Immun. 1993;61:1055-1061.
33. 33. See RH, Chow AW. Staphylococcal toxic shock syndrome toxin 1-induced tumor necrosis factor alpha and interleukin-1b secretion by human peripheral blood monocytes and T lymphocytes is differentially suppressed by protein kinase inhibitors. Infect Immun. 1992;60:3456-3459.
34. 34. Balaban N, Novick RP. Autocrine regulation of toxin synthesis by Staphylococcus aureus. Proc Natl Acad Sci. 1995; 92:1619-1623.
35. 35. Gillaspy AF, Hickmon SG, Skinner RA, et al. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun. 1995;63:3373-3380.
36. 36. Novick RP, Ross HF, Projan SJ, et al. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J. 1993;12:3967-3975.
37. 37. Projan SJ, Skrobot-Brown S, Schlievert PM, et al. Glycerol monolaurate inhibits the production of beta lactamase, toxic shock syndrome toxin 1, and other staphylococcal exoproteins by interfering with signal transduction. J Bacteriol. 1994;176:4204-4209.
38. 38. Bremell T, Tarkowski A. Preferential induction of septic arthritis and mortality by superantigen-producing staphylococci. Infect Immun. 1995;63:4185-4187.
39. 39. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev. 1995;8:411-426.
40. 40. Waldvogel F. New insights into septic and toxic diseases produced by Staphylococcus aureus. Curr Opin Infect Diseases. 1995;8(suppl):S3-S6.
41. 41. Dai R, Grammer SF, Fresh and cultured Langerhans cells display differential capacities to activate hapten-specific T cells. J Immunol. 1993;150:59-66.
42. 42. Nickoloff BJ, Mitra RS. Accessory cell function of keratinocytes for superantigens: dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol. 1993;150:2148-2159.
43. 43. Polk HC, George CD, Wellhausen SR, et al. A systematic study of host defense processes in badly injured patients. Ann Surg. 1986;204:282-299.
44. 44. Moore FA, Moore EE. Evolving Concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995;75:257-277.
45. 45. Buffone V, Meakins JL. Neutrophil function in surgical patients. Arch Surg. 1984;119:39-43.
46. 46. Hebert JC, O'Reilly M. Modifying the host response to injury: the future of trauma care. Surg Clin North Am. 1995;75:335-349.
47. 47. Baker CC, Huynh T. Sepsis in the critically ill patient. Curr Probl Surg. 1995;32:1013-1092.
48. 48. Anding K, Kropec A, Schmidt-Eisenlohr E, et al. Enhancement of in vitro bactericidal activity of neutrophils from trauma patients in the presence of granulocyte colony-stimulating factor. Eur J Clin Microbiol Infect Dis. 1993;12:121-124.
49. 49. Petersen EA, Mandel RM. Infectious diseases: old diseases return and new agents emerge. Arch Intern Med. 1995;155:1571-1572.
50. 50. Murray BE. Can antibiotic resistance be controlled? NEJM. 1994;330:1229-1230.
51. 51. Service RF. Antibiotics that resist resistance. Science. 1995;270:724-727.
52. 52. Shapiro MA, Dever JA, Joannides ET, et al. In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1995;39:2183-2186.
53. 53. Neu HC. Emergence and mechanisms of bacterial resistance in surgical infections. Am J Surg. 1995;169(suppl. 5A):13-19.
54. 54. Kayser FH. Methicillin and glycopeptide resistance in staphylococci: a new threat? Curr Opin Infect Dis. 1995;8(suppl):S7-S11.
55. 55. Jacoby GA, Archer GL. New Mechanisms of bacterial resistance to antimicrobial agents. NEJM. 1991;324:601-609.
56. 56. Chambers HF. Detection of methicillin-resistant staphylococci. Infect Dis Clin North Am. 1993;7:425-431.
57. 57. Vannuffel P, Gigi J, Ezzedine H, et al. Specific detection of methicillin-resistant staphylococcus species by multiplex PCR. J Clin Microbiol. 1995;33:2864-2867.
58. 58. Kaatz GW, Seo SM. Emergence of teicoplanin resistance during therapy of S. aureus endocarditis. J Infect Dis. 1990;162:103-108.
59. 59. Noble WC, Virani Z. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to S. aureus. FEMS Microbiol Lett. 1992;93:195-198.
60. 60. Georgopapadakou NH. Minireview: penicillin-binding proteins and bacterial resistance to beta lactams. Antimicrob Agents Chemother. 1993;37:2045-2053.
61. 61. Kaatz GW, Seo SM. Inducible NorA-mediated multidrug resistance in Staphylococcus aurcus. Antimicrob Agents Chemother. 1995;39:2650-2655.
62. 62. Bandyk DF, Esses GE. Prosthetic graft infections. Surg Clin North Am. 1994;74:571-590.
63. 63. Schmitt DD, Bandyk DF, Bacterial adherence to vascular prostheses: a determinant of graft infectivity. J Vasc Surg. 1986;3:732-740.
64. 64. Bricker DL, Beall AC, DeBakey ME. The differential response to infection of autogenous vein versus Dacron arterial prosthesis. Chest. 1970;58:566-570.
65. 65. Yamamura K, Sakurai T, Yano K, et al. Prevention of vascular graft infection by Sisomicin incorporated into fibrin glue. Microbiol Immunol. 1995;39:895-896.
66. 66. Garrison RN, Wilson MA. Intravenous and central catheter infections. Surg Clin North Am. 1994;74:557-570.
67. 67. Moreno F, Crisp C, Jorgensen JH, Patterson JE. Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis. 1995;21:1308-1312.
68. 68. Raad I. Antibiotics and Prevention of microbial colonization of catheters. Antimicrob Agents Chemother. 1995;39:2397-2400.
69. 69. Garcia N, Mileski WJ, Lipsky P. Differential effects of monoclonal antibody blockade of adhesion molecules on in vitro susceptibility to soft tissue infection. Infect Immun. 1995;63:3816-3819.
70. 0. Wurtz R. Infection control in public hospitals. Infect Control Hosp Epidemiol. 1995;16:642-646.
71. 71. Gaynes R. Surveillance of antibiotic resistance: learning to live with bias. Infect Control Hosp Epidemiol. 1995;16:623-626.
72. 72. Lorian V. The need for surveillance for antimicrobial resistance. Infect Control Hosp Epidemiol. 1995;16:638-641.
73. 73. Kernodle DS, McGraw PA, Barg NL et al. Growth of Staphylococcus aureus with Nafcillin in vitro induces alpha toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis. 1995;172:410-9.
74. 74. Sato M, Tsuchiya H, Miyazaki T, et al. Antibacterial activity of flavanostilbenes against methicillin-resistant Staphylococcus aureus. Lett Appl Microbiol. 1995;21:219-222.
75. 75. Kokoshis PL, Williams DL, Cook JA, Di Luzio NR. Increased resistance to Staphylococcus aureus infection and enhancement in serum lysozyme activity by glucan. Science. 1978; 199:1340-1342.
76. 76. Felippe J, Silva M. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynec Obstet. 1993;177:383-388.